, ECR double aveugle de supériorité, vol.2013

, Commission de la Transparence : rapport d'évaluation des médicaments anticoagulants oraux, HAS, 2016.

J. A. Sterne, P. N. Bodalia, P. A. Bryden, P. A. Davies, J. A. López-lópez et al., Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis, Health Technol Assess, vol.21, issue.9, pp.1-386, 2017.

. Michel, Perception de l'utilisation des anticoagulants oraux directs : enquête auprès des médecins généralistes, 2014.

P. Frappé and J. Cogneau, Nouveaux anticoagulants oraux : à qui les prescrivons-nous ? Etude Cacao / phase, p.12

. Vidal--rivaroxaban, , 2019.

. Vidal--pradaxa, 150 mg gél -Pharmacodynamie, 2019.

, Les anticoagulants oraux

H. Autorité-de-santé, , 2019.

P. Albaladejo, G. Pernod, A. Godier, E. De-maistre, N. Rosencher et al., Prise en charge des hémorragies et des gestes invasifs urgents chez les patients recevant un anticoagulant oral et direct anti-IIa (dabigatran), p.22

E. Investigators, R. Bauersachs, S. D. Berkowitz, B. Brenner, H. R. Buller et al., Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.363, issue.26, pp.2499-510, 2010.

E. Investigators, H. R. Büller, M. H. Prins, A. Lensin, H. Decousus et al., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, vol.366, issue.14, pp.1287-97, 2012.

S. Schulman, A. K. Kakkar, S. Z. Goldhaber, S. Schellong, H. Eriksson et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, vol.129, issue.7, pp.764-72, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01030866

-. Hokusai, . Investigators, H. R. Büller, H. Décousus, M. A. Grosso et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, vol.369, issue.15, pp.1406-1421, 2013.

G. Agnelli, H. R. Buller, A. Cohen, M. Curto, A. S. Gallus et al., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, vol.369, issue.9, pp.799-808, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00932477

S. Schulman and C. Kearon, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, Journal of Thrombosis and Haemostasis, vol.3, issue.4, pp.692-696, 2005.

. Es-n-van, M. Coppens, S. Schulman, S. Middeldorp, and H. R. Büller, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, vol.124, issue.12, pp.1968-75, 2014.

A. T. Cohen, M. Hamilton, S. A. Mitchell, H. Phatak, X. Liu et al., Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS ONE, vol.10, issue.12, p.144856, 2015.

J. A. Heit, F. A. Spencer, and R. H. White, The epidemiology of venous thromboembolism, J Thromb Thrombolysis, vol.41, issue.1, pp.3-14, 2016.

H. R. Buller, Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study, Blood, vol.114, issue.22, pp.2-2, 2009.

S. Schulman, C. Kearon, A. K. Kakkar, S. Schellong, H. Eriksson et al., Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism, New England Journal of Medicine, vol.368, issue.8, pp.709-727, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00935796

J. I. Weitz, A. Lensing, M. H. Prins, R. Bauersachs, J. Beyer-westendorf et al., Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism, N Engl J Med, vol.30, issue.13, pp.1211-1233, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02051875

G. Agnelli, H. R. Buller, A. Cohen, M. Curto, A. S. Gallus et al., Apixaban for extended treatment of venous thromboembolism, N Engl J Med, vol.368, issue.8, pp.699-708, 201321.
URL : https://hal.archives-ouvertes.fr/hal-00771313

S. K. Kakkos, G. I. Kirkilesis, and I. A. Tsolakis, Editor's Choice -Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials, European Journal of Vascular and Endovascular Surgery, vol.48, issue.5, pp.565-75, 2014.

A. T. Cohen, M. Hamilton, A. Bird, S. A. Mitchell, S. Li et al., Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS ONE, vol.11, issue.8, p.160064, 2016.

J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, Epidemiology of cancerassociated venous thrombosis, Blood, vol.122, issue.10, pp.1712-1735, 2013.

G. Agnelli, C. Becattini, R. Bauersachs, B. Brenner, M. Campanini et al., Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study, Thromb Haemost, vol.118, issue.9, pp.1668-78, 2018.

G. E. Raskob, N. Van-es, P. Verhamme, M. Carrier, D. Nisio et al., Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism, N Engl J Med, vol.378, issue.7, pp.615-639, 2018.

A. M. Young, A. Marshall, J. Thirlwall, O. Chapman, A. Lokare et al., Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial

, J Clin Oncol, vol.36, issue.20, pp.2017-2040, 2018.

A. Li, D. A. Garcia, G. H. Lyman, and M. Carrier, Direct oral anticoagulant (DOAC) versus lowmolecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis, Thromb Res, vol.173, pp.158-63, 2019.

M. C. Vedovati, M. Giustozzi, G. Bonitta, G. Agnelli, and C. Becattini, Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis, Thrombosis Research, vol.170, pp.175-80, 2018.

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

S. J. Connolly, J. Eikelboom, C. Joyner, H. Diener, R. Hart et al., Apixaban in patients with atrial fibrillation, N Engl J Med, vol.364, issue.9, pp.806-823, 2011.

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet, vol.383, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

A. T. Cohen, N. R. Hill, X. Luo, C. Masseria, S. A. Abariga et al., A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants, Int J Cardiol, vol.269, pp.174-81, 2018.

O. Sanchez, Y. Benhamou, L. Bertoletti, J. Constans, F. Couturaud et al.,

, Rev Mal Respir, 2019.

C. Kearon, E. A. Akl, J. Ornelas, A. Blaivas, D. Jimenez et al.,

A. Therapy and . Vte-disease, CHEST Guideline and Expert Panel Report. Chest, vol.149, issue.2, pp.315-52, 2016.

S. V. Authors/task-force-members-;-konstantinides, G. Meyer, C. Becattini, H. Bueno, and G. Geersing, The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), Eur Respir J, 2019.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

C. T. January, L. S. Wann, H. Calkins, L. Y. Chen, J. E. Cigarroa et al., , 2019.

. Aha/acc/hrs-focused, AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, vol.74, issue.1, pp.104-136, 2009.

M. Maeder, Etude descriptive de la Prescription des Anticoagulants Oraux dans des cabinets de Médecine Générale, 2016.

M. E. Pineau, Rôle du cardiologue dans la prescription des innovations thérapeutiques par les médecins généralistes de Midi Pyrénées : A propos des anticoagulants oraux directs, 2016.

H. Autorité-de-santé, HAS : Commission de la transparence Avis Dabigatran, 2018.

M. Carrier, Évaluation des pratiques des médecins généralistes sur la prescription des anticoagulants oraux directs (dabigatran pradaxa ® , rivaroxaban xarelto ® et apixaban eliquis ® ) chez les personnes âgées de plus de 75 ans sur le secteur sanitaire palois, 2015.

M. Grillet, Modalités de prescription des anticoagulants oraux directs en 2015-2016 en Aveyron, 2016.

C. Chardon, S. Figon, C. Université, (. Bernard, and . Lyon, Perception des anticoagulants oraux directs chez les médecins généralistes en Rhône-Alpes: étude qualitative par focus groups auprès de 19 médecins généralistes, 2014.

A. Douros, M. Durand, C. M. Doyle, S. Yoon, P. Reynier et al., Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies, Drug Saf, 2019.

F. Moustafa, R. Pesavento, P. Micco, . Di, J. González-martínez et al., Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants, Clinical Pharmacology & Therapeutics, vol.103, issue.4, pp.684-91, 2018.

. Praxbind,

. Vidal, , 2019.

M. Santé, . Et-de-la, and M. Santé,

S. Ministère-des, L. De, and . Santé, , 2019.